Category Archives: Regenerative Medicine

Mayo Clinic #39;s Abba Zubair Speaking at #WSCS14
Dr. Abba Zubair, Medical Director of the Transfusion Medicine and Stem Therapy Laboratory at Mayo Clinic in Florida speaking on his topic "Application of Microgravity Expanded Stem Cells in...

By: Mayo Clinic

Go here to read the rest:
Mayo Clinic's Abba Zubair Speaking at #WSCS14 - Video

Tampa, FL (PRWEB) December 30, 2014

In February 2015, Regenerative Medicine Solutions (RMS) will open a new clinic in Scottsdale, AZ under the Lung Institute brand. This expansion of the Lung Institute marks its third location in the country. With locations in both Tampa and Nashville, the Lung Institute has made a positive impact in the lives of their patients and the surrounding communities.

RMS started as a single treatment center in 2012 in Tampa with a goal of providing progressive therapies for debilitating diseases. At inception, RMS began its mission with fewer than 10 employees. Through dedication and a focus on its mission, RMS expanded the Lung Institute successfully to a second location in Nashville, TN in October 2014. The immediate success of the Nashville location has driven plans for continued growth westward into Scottsdale, AZ.

The RMS model of combining innovative technology and advanced stem cell treatments has led to the successful care of hundreds of patients. RMS is paving the way for future integration of revolutionary processes in the field of regenerative medicine. The Lung Institute is specifically committed to providing patients with an effective way to treat pulmonary conditions, rather than just manage their symptoms.

An official ribbon cutting ceremony will be held at the new Scottsdale facility, with the medical staff, RMS corporate team, and members of the Scottsdale and Phoenix Chambers of Commerce and community representatives in attendance.

We are excited to be expanding the Lung Institute to Arizona, says Lynne Flaherty, Executive Vice President of RMS. Patients from this region of the country will now have access to a clinic closer to home.

About Regenerative Medicine Solutions Regenerative Medicine Solutions (RMS) is a leading global provider of innovative regenerative technologies that treat an array of debilitating medical conditions. In addition, the company is the owner and operator of the Sleep Apnea Institute and the Lung Institute. Committed to an individualized patient-centric approach, RMS consistently provides the highest quality of care while producing positive outcomes. By applying modern-day best practices to the growing field of regenerative medicine, RMS is changing lives. For more information, visit our website at myregenmed.com, like us on Facebook, follow us on Twitter or call us today at (877) 867-4551.

The rest is here:
Regenerative Medicine Solutions to Open New Lung Institute Clinic in 2015

Portable Laminar Flow Hood for Stem Cell Analysis and Regenerative Medicine
Sentry Air Systems #39; ISO Class 5 Portable Clean Room Hood [Laminar Flow Hood] uses ductless technology and high quality HEPA filtration to create a positive p...

By: SentryAir

Continue reading here:
Portable Laminar Flow Hood for Stem Cell Analysis and Regenerative Medicine - Video

Sanford Consortium for Regenerative Medicine
The Sanford Consortium for Regenerative Medicine (SCRM) combines the intellectual capital of five world-class biomedical research institutions to pursue research projects in stem cell science,...

By: ACI San Diego

Read more from the original source:
Sanford Consortium for Regenerative Medicine - Video

(PRWEB UK) 4 December 2014

Users of RegMedNet will be able to view featured articles, interviews, webinars, industry news from FSG and select partners and much more. The site features selected content from the peer-reviewed journal Regenerative Medicine and highlights key content from other related journals. Site content and functionality is entirely free to all site registrants.

RegMedNet will provide a virtual meeting place for experts in this exciting field said Alexandra Thompson, Community Manager at FSG. This field is constantly evolving, and this platform, on which members can drive the content themselves, will open a wider debate and help move the field further forward. With content and expertise shared from all areas of the field, RegMedNet is all about collaborative working and the dissemination of knowledge.

Think of it as something that combines LinkedIn with Skype with blogging but dedicated to the RegMed community said Phil Garner, Managing Director at FSG. Users can access up-to-date information and opinion, as well as communicate and collaborate with each other by using messaging and video capabilities of the site.

RegMedNet (http://www.regmednet.com) is now live and registration is free. To launch the site, Network representatives are currently introducing RegMedNet to participants at the 2014 World Stem Cell Summit (WSCS) in San Antonio, Texas, USA (stand #43) from Dec 3-5.

WSCS is the largest interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community and charting the future of this burgeoning field. The WSCS attracts more than 1,400 attendees from industry, academia and government from 40 countries worldwide.

For further information please contact: Elena Woodstock, Marketing and Public Relations, Future Science Group T: +44 (0) 20 8371 6090 F: +44 (0) 20 8343 2313 E: e.woodstock(AT)future-science-group.com

NOTES FOR EDITORS ABOUT REGENERATIVE MEDICINE ISSN: 1746-0751/1746-076X Volume: Number 9 (2014) Frequency: 8 issues per year Senior Editor: Chris Mason, University College London, UK

Description: Regenerative Medicine provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats vital to an increasingly time-constrained community.

Coverage includes:

See more here:
Future Science Group launches RegMedNet at the World Stem Cell Summit

MIAMI (PRWEB) December 01, 2014

MIAMI, Dec. 1, 2014Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.

The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course is to be held four times in Miami in 2015.

Course details, objectives and instruction include:

Didactic Lectures will include:

For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

More here:
Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and ...

MEDIPOST America
Antonio Lee, Ph.D., CEO Managing Director Private Company Headquarters: Maryland, U.S. MEDIPOST is a leading stem cell biotechnology company focused on dev...

By: Alliance for Regenerative Medicine

See the original post here:
MEDIPOST America - Video

PUBLIC RELEASE DATE:

24-Nov-2014

Contact: Fco. Javier Alonso fjalonso@bib.uc3m.es Carlos III University of Madrid @uc3m

This news release is available in Spanish.

The new Chair springs from the desire to boost biomedical research in pathologies that do not have adequate treatment, above all, in the area of genodermatosis and other skin diseases, in addition to developing innovative therapies that could the subject of clinical trials with patients.

As reflected in the agreement, the Chair's goal is to constitute a research team that is able to generate innovative therapeutic technologies at the national and international level, develop products with a biotechnological base that can benefit patients, foment doctoral theses focusing on this field, and also carry out the dissemination of information at scientific conferences and among the general public. The Chair will be headed by Professor Marcela del Ro Nechaevsky, from the Bioengineering Department at UC3M and the CIEMAT-CIBER Unit of Regenerative Medicine for Rare Diseases.

Among the activities to be carried out under the Chair's support are clinical characterization, physiopathology, cellular and genetic genodermatosis (genetic skin diseases); use of adult stem cells (mesenchymal and epitheial) for cutaneous skin regeneration; and use of 3D matrix carriers of adult stem cells to develop humanized research models and their application in pre-clinical trials

Use of adult stem cells

The Chair, which at the moment also encompasses some twenty researchers, will also carry out work in the area of gene therapy through the use genetically modified stem cells along two lines: its use as bioreactors for factors with biological activity and for pathological phenotype correction in genodermatosis. According to the Chair's Head, Marcela del Ro Nechaevsky, this iniciative will allow "quality research to be carried out and foment its transfer to benefit patients." The aim is to achieve pre-clinical results that in the middle term allow effective transfer to medical practice.

After signing the agreement, the president of the Fundacin Jimnez Daz Health Research Institute (IISFJD), Juan Antonio lvaro de la Parra, reflected that "this Chair will allow us to transfer all the knowledge generated by this research team to society."

See the original post here:
UC3M, IISFJD and CIEMAT create a Chair for Regenerative Medicine and Tissue Bioengineering

(MENAFN - ProactiveInvestors)

Regenerative medicine company Regeneus Ltd () will increase its focus on partnering to commercialise its products as well as streamline operations and reduce costs.

The company is in discussions with potential partners about the licensing development and distribution of its allogeneic stem cell products.

In a wide reaching strategic review of operations outlined at the recent AGM the successful measures and cost reductions will see Regeneus on track to meet its reduced quarterly cash burn target of 1.7 million.

Significantly this will provide an expected two year cash runway.

Completion of the early stage research and development phases for a number of products now allows a greater focus on partnering and commercialisation.

New CEO John Martin said: our review identified a number of opportunities for streamlining our management structure and operations without having any significant impact on meeting our business and product development milestones for the next 18 months.

"We have increased our focus on licensing commercialisation partners for the co-development and distribution of products. HiQCell Kvax and our stem cell secretions cream are all at the stage where they can be commercialised and we are currently engaged with a number of parties about the distribution of these products.

"We are also in discussions with potential partners about the licensing development and distribution of our allogeneic stem cell products CryoShot and Progenza (PRG).

Martin said further: We have successfully completed an expensive phase in the development of our products. The Kvax vaccine manufacturing process is complete and has been transferred to Hennessey our manufacturing partner in the US.

The rest is here:
Regeneus in commercialisation discussions reduces costs in review

Eli Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
In a specially designed facility that is compliant with FDA Good Manufacturing Practices (GMP) requirements, scientists with the Eli and Edythe Center of Reg...

By: UCLA Eli Edythe Broad Center of Regenerative Medicine and Stem Cell Research

See the original post:
Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA - Video